← FDA DRUG APPROVALS

FDA ANDA · ANDA076155

IPRATROPIUM BROMIDE

Sponsor: APOTEX INC

APPLICATION
ANDA076155
TYPE
ANDA
ORIGINAL APPROVAL
2003-04-18
LATEST ACTION
2015-11-18
ROUTE
NASAL
DOSAGE FORM
SPRAY, METERED
MARKETING STATUS
Prescription

Products

IPRATROPIUM BROMIDEPrescription
IPRATROPIUM BROMIDE 0.042MG/SPRAY · SPRAY, METERED · NASAL

Approval history

2015-11-18Labeling · Supplement 22 · standardAP
2009-03-24Labeling · Supplement 15AP
2007-05-22Labeling · Supplement 11AP
2003-04-18OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →